Skip to main content

Table 2 Costs in China

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Parameters name

Base (RMB)

Range (RMB)

Distribution

Source

Olaparib (150 mg)

102

89.76 ~ 442.68

–

www.yaozh.com

Olaparib (per cycle)

12,240

10,771.2 ~ 53,121.60

Triangle

www.yaozh.com

Placebo (per cycle)

–

–

–

–

Paclitaxel (100 mg)

802.7

602.0 ~ 1003.39

–

[1]

Paclitaxel (per cycle)

3082.37

2311.68 ~ 3853.02

Triangle

–

BRCA1/2 gene testing

532.61

426.09 ~ 639.14

Triangle

[2]

Laboratory testing (per cycle)

211.01

26.25 ~ 228.32

Triangle

[3]

Nursing fees (per cycle)

1350

900 ~ 2400

Triangle

Tertiary hospitals

Regular follow-up (per cycle)

260.49

208.37 ~ 312.63

Triangle

[10]

Imaging evaluation (per cycle)

89.57

57.49 ~ 119.7

Triangle

[11]

Injection fees (per cycle)

12

–

–

Tertiary hospitals

Bed charges (per cycle)

1950

30 ~ 150

Triangle

Tertiary hospitals

Cost of adverse reaction treatment

    

Anemia

4087.7

3066.18 ~ 5110.04

Triangle

[4]

Fatigue

625.63

567.75 ~ 683.51

Triangle

[12]

Decrease in neutrophil count

4793.67

3834.94 ~ 5752.4

Triangle

[5]

  1. RMB renminbi (Chinese currency)